DR. KENNETH CARL ANDERSON, MD
Osteopathic Medicine at Binney St, Boston, MA
License number
Massachusetts 45550
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
440 Binney St, Boston, MA 02115
264 Weston Rd, Wellesley, MA 02482
264 Weston Rd, Wellesley, MA 02482
Phone
(617) 632-2144
(617) 632-2140 (Fax)
(781) 537-6209
(617) 632-2140 (Fax)
(781) 537-6209
Personal information
See more information about KENNETH CARL ANDERSON at radaris.comName
Address
Phone
49 Ridgecrest Ter Apt 16, West Roxbury, MA 02132
Professional information
Attorney At Byrne &Amp; Drechsler, Llp
Position:
Attorney at Byrne & Drechsler, LLP
Location:
Greater Boston Area
Industry:
Law Practice
Work:
Byrne & Drechsler, LLP
-
Attorney
Suffolk County District Attorneys Office
1992 - 1998
-
Assistant District Attorney
Education:
Suffolk University Law School 1988 - 1990
Juris Doctor Wake Forest University School of Law 1987 - 1988
Juris Doctor Wake Forest University School of Law 1987 - 1988
Dr. Kenneth C Anderson, Boston MA - MD (Doctor of Medicine)
Specialties:
Pulmonology, Hospice & Palliative Medicine, Sleep Medicine
Address:
Dana Faber Cancer Institute
44 Binney St, Boston 02115
(617) 632-2144 (Phone)
4003 Kresge Way, Louisville 40207
(502) 899-7377 (Phone)
44 Binney St, Boston 02115
(617) 632-2144 (Phone)
4003 Kresge Way, Louisville 40207
(502) 899-7377 (Phone)
Certifications:
Hospice Care and Palliative Medicine, 2008, Internal Medicine, 1990, Pulmonary Disease, 1994, Sleep Medicine, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Dana Faber Cancer Institute
44 Binney St, Boston 02115
4003 Kresge Way, Louisville 40207
Brigham and Women's Hospital
75 Francis St, Boston 02115
Dana - Farber Cancer Institute
450 Brookline Ave, Boston 02115
44 Binney St, Boston 02115
4003 Kresge Way, Louisville 40207
Brigham and Women's Hospital
75 Francis St, Boston 02115
Dana - Farber Cancer Institute
450 Brookline Ave, Boston 02115
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1977
University Louisville Affil Hosps
Graduated: 1989
Graduated: 1991
Johns Hopkins University School Of Medicine
Graduated: 1977
University Louisville Affil Hosps
Graduated: 1989
Graduated: 1991
Consulting Actuary At The Kenneth D. Anderson Company, Inc.
Position:
Consulting Actuary at The Kenneth D. Anderson Company, Inc.
Location:
Greater Boston Area
Industry:
Financial Services
Work:
The Kenneth D. Anderson Company, Inc.
-
Consulting Actuary
Kenneth Carl Anderson, Boston MA
Specialties:
Internist
Address:
450 Brookline Ave, Boston, MA 02215
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Methods Of Using [3.2.0] Heterocyclic Compounds And Analogs Thereof In Treating Waldenstrom's Macroglobulinemia
US Patent:
8394816, Mar 12, 2013
Filed:
Dec 5, 2008
Appl. No.:
12/329504
Inventors:
Irene Ghobrial - Chestnut Hill MA, US
Aldo Roccaro - Boston MA, US
Dharminder Chauhan - Natick MA, US
Kenneth Anderson - Wellesley MA, US
Michael Palladino - Olivenhain CA, US
Aldo Roccaro - Boston MA, US
Dharminder Chauhan - Natick MA, US
Kenneth Anderson - Wellesley MA, US
Michael Palladino - Olivenhain CA, US
International Classification:
A61K 31/44, A61K 31/42, A61K 31/40
US Classification:
514290, 514375, 514421
Abstract:
Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.
Methods And Compositions For Treating Cancer Using Proteasome Inhibitors
US Patent:
2012021, Aug 23, 2012
Filed:
Sep 23, 2011
Appl. No.:
13/242209
Inventors:
Kenneth C. Anderson - Wellesley MA, US
Teru Hideshima - Brookline MA, US
Constantine S. Mitsiades - Boston MA, US
Nicholas Mitsiades - Roxbury MA, US
Teru Hideshima - Brookline MA, US
Constantine S. Mitsiades - Boston MA, US
Nicholas Mitsiades - Roxbury MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 31/69, A61K 31/197, A61P 35/00, A61K 31/704
US Classification:
514 34, 514564, 514 64
Abstract:
The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.
Ccr1 Inhibitors Useful For The Treatment Of Multiple Myeloma And Other Disorders
US Patent:
2009028, Nov 19, 2009
Filed:
Dec 17, 2008
Appl. No.:
12/316901
Inventors:
Ole Petter Veiby - Westborough MA, US
Kenneth C. Anderson - Wellesley MA, US
Sonia Vallet - Boston MA, US
Kenneth C. Anderson - Wellesley MA, US
Sonia Vallet - Boston MA, US
Assignee:
Millennium Pharmaceuticals Inc. - Cambridge MA
International Classification:
A61K 31/4545, A61P 35/00
US Classification:
514291
Abstract:
The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.
Use Of C-Kit Inhibitors For The Treatment Of Myeloma
US Patent:
2004026, Dec 30, 2004
Filed:
Aug 5, 2004
Appl. No.:
10/489643
Inventors:
Kenneth Anderson - Wellesley MA, US
International Classification:
A61K031/53, A61K031/501, C 07D 4 3/02
US Classification:
514/252020, 514/252030, 514/242000, 544/183000, 544/238000
Abstract:
The present invention relates to the use of a c-kit inhibitor, especially a c-kit inhibitor of formula I, wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising a c-kit inhibitor and a compound effecting apoptosis of myeloma cells, preferably dexamethasone, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.
Use Of Staurosporine Derivatives For The Treatment Of Multiple Myeloma
US Patent:
2009028, Nov 19, 2009
Filed:
Dec 7, 2005
Appl. No.:
11/721094
Inventors:
D. Gary Gilliland - Wellesley MA, US
James Douglas Griffin - Brookline MA, US
Jing Chen - Atlanta GA, US
Kenneth C. Anderson - Wellesley MA, US
James Douglas Griffin - Brookline MA, US
Jing Chen - Atlanta GA, US
Kenneth C. Anderson - Wellesley MA, US
International Classification:
A61K 31/553, C07D 245/06, A61P 35/00
US Classification:
51421108, 540469, 514183
Abstract:
The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving ras or FGFR3 signalling pathways and l or c-fos transcription, especially for the curative and/or prophylactic treatment of myeloma or multiple Myeloma, and to a method of treating diseases involving ras or FGFR3 signalling pathways and/or c-fos transcription.
Compositions, Kits, And Methods For Identification, Assessment, Prevention, And Therapy Of Cancer
US Patent:
8211634, Jul 3, 2012
Filed:
Feb 13, 2007
Appl. No.:
11/706155
Inventors:
Ronald A. DePinho - Houaton TX, US
Kenneth C. Anderson - Wellesley MA, US
Ruben D. Carrasco - Brookline MA, US
Giovanni Tonon - Cernusco Sul Naviglio, IT
Cameron W. Brennan - Haworth NJ, US
Lynda Chin - Houston TX, US
Kenneth C. Anderson - Wellesley MA, US
Ruben D. Carrasco - Brookline MA, US
Giovanni Tonon - Cernusco Sul Naviglio, IT
Cameron W. Brennan - Haworth NJ, US
Lynda Chin - Houston TX, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
Board of Trustees of the University of Arkansas - Little Rock AR
Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
C12Q 1/68, G01N 33/53, G01N 33/574
US Classification:
435 6, 434 71, 434 723
Abstract:
The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.